Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06049667
Other study ID # NTQ2494-23101
Secondary ID
Status Recruiting
Phase Phase 1
First received
Last updated
Start date August 7, 2023
Est. completion date August 2026

Study information

Verified date September 2023
Source Nanjing Chia-tai Tianqing Pharmaceutical
Contact Yu meng Zhou
Phone 86-025-85109999
Email yumeng_zhou@163.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

NTQ2494 tablet, an anti-tumor molecular targeted drug, is an AXL kinase inhibitor. The objectives were to evaluate the safety and tolerability, PK characteristics and preliminary efficacy of NTQ2494 tablets in patients with advanced hematological malignancies.


Recruitment information / eligibility

Status Recruiting
Enrollment 72
Est. completion date August 2026
Est. primary completion date August 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. =18 years in age, male or female. 2. Relapsed/refractory AML patients. 3. ECOG performance status score is 0 to 2. 4. Life expectancy of at least 3 months. 5. Adequate bone marrow and good organ function. 6. Ability to understand the purpose and risks of the study and the willingness to sign a written informed consent document. Exclusion Criteria: 1. Receiving anticancer therapy including immunotherapy, targeted therapy, endocrine therapy, radiotherapy and chemotherapy within 2 weeks or 5 half-lives (whichever is longer) prior to starting study treatment. 2. Receiving any other investigational agents within 4 weeks prior to starting study treatment. 3. Having major surgery within 4 weeks prior to starting study treatment, or intended to undergo surgery during the trail. 4. AML with any of the following: 1) acute promyelocytic leukemia; 2) AML with blast crisis of chronic myelogenous leukemia; 3) central nervous system leukemia. 5. Prior or current other malignancy (except cured noninvasive basal cell or squamous cell skin cancer and/or other cured carcinoma in situ; except for other malignancies that have achieved clinical cure for > 5 years and have not recurred within 5 years).History of severe cardiovascular or cerebrovascular disease. 6. Use of strong inhibitors or strong inducers of CYP3A4 or P-gp within 7 days prior to starting study treatment. 7. Receiving (attenuated) live vaccines within 4 weeks prior to starting study treatment and/or planning to receive (attenuated) live vaccines during the trial. 8. With unresolved clinically significant non-hematological toxicities from prior AML therapy (chemotherapy, targeted therapy, immunotherapy, radiotherapy and surgery), defined as any grade 2 or higher grade (CTCAE v5.0), alopecia and other events that are tolerable as judged by the investigator. 9. Patients who have received previous allogeneic hematopoietic stem cell transplantation; or received autologous hematopoietic stem cell transplantation within 3 months prior to starting study treatment. 10. Unable to swallow oral tablets, or other conditions seriously affecting gastrointestinal absorption judged by the investigator. 11. Patients with uncontrolled infections unsuitable for the trail judged by the investigator. 12. Known infection with hepatitis B, hepatitis C, HIV or Syphilis. 13. Known alcohol or drug dependence. 14. Patients with mental disorders or poor compliance. 15. Patients with a previous history of severe allergy to any drug or food. 16. Lactating or pregnant female, and females or males (or partners) who plan to pregnant and do not agree to use adequate contraception for the duration of the trail and up to 3 months after completion of the last study treatment. 17. Other reasons judged by the investigator that the patients unsuitable for the trail.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
NTQ2494 tablet
Drug: NTQ2494 tablet Part 1: Dose escalation, single and multiple doses of NTQ2494 with dose modifications based on tolerability criteria. For each dose level, a single dose of NTQ2494 tablets will be first administered orally, then continuous 28-day treatment will start (per cycle). Part 2: Dose expansion, recommended doses from Part 1. For each dose level, multiple doses of NTQ2494 tablets will be administered as 28-day treatment (per cycle).

Locations

Country Name City State
China Hematology Hospital of the Chinese Academy of Medical Sciences Tianjin Tianjin

Sponsors (1)

Lead Sponsor Collaborator
Nanjing Chia-tai Tianqing Pharmaceutical

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Maximum tolerance dose (MTD) and dose limiting toxicity (DLT) MTD is defined as the maximum dose level at which no more than 1 of 3 participants experience a DLT within the days of single dose and the first 28 days of multiple doses in dose escalation part. 30 days
Secondary Cmax of single dose At the end of Cycle 1 (each cycle is 28 days)
Secondary AUC0-t of single dose At the end of Cycle 1 (each cycle is 28 days)
Secondary AUC0-8 of single dose At the end of Cycle 1 (each cycle is 28 days)
Secondary Tmax of single dose At the end of Cycle 1 (each cycle is 28 days)
Secondary t1/2z of single dose At the end of Cycle 1 (each cycle is 28 days)
Secondary Vz/F of single dose At the end of Cycle 1 (each cycle is 28 days)
Secondary CLz/F of single dose At the end of Cycle 1 (each cycle is 28 days)
Secondary ?z of single dose At the end of Cycle 1 (each cycle is 28 days)
Secondary MRT0-t of single dose At the end of Cycle 1 (each cycle is 28 days)
Secondary Rac of AUC and Cmax of first 28 days of multiple doses At the end of Cycle 1 (each cycle is 28 days)
Secondary DF of AUC and Cmax of first 28 days of multiple doses At the end of Cycle 1 (each cycle is 28 days)
Secondary Css,max of first 28 days of multiple doses At the end of Cycle 1 (each cycle is 28 days)
Secondary Css,min of first 28 days of multiple doses At the end of Cycle 1 (each cycle is 28 days)
Secondary AUCss of first 28 days of multiple doses At the end of Cycle 1 (each cycle is 28 days)
Secondary Cav of first 28 days of multiple doses At the end of Cycle 1 (each cycle is 28 days)
Secondary Tss,max of first 28 days of multiple doses At the end of Cycle 1 (each cycle is 28 days)
Secondary t1/2 of first 28 days of multiple doses At the end of Cycle 1 (each cycle is 28 days)
Secondary Vz/F of first 28 days of multiple doses ?Vz/F?CLss/F??z of first 28 days of multiple doses. At the end of Cycle 1 (each cycle is 28 days)
Secondary CLss/F of first 28 days of multiple doses At the end of Cycle 1 (each cycle is 28 days)
Secondary ?z of first 28 days of multiple doses At the end of Cycle 1 (each cycle is 28 days)
Secondary Objective response rate (ORR) ORR is defined as the proportion of subjects with confirmed CRc or PR. through study completion, an average of 1 year
Secondary Composite response (CRc) rate CRc rate is defined as the proportion of subjects with confirmed CR or CRi or CRh. through study completion, an average of 1 year
Secondary Duration of response (DOR) DOR is defined as the duration from the date of the first documented response of CR or PR to the date of the first documented recurrence or death. through study completion, an average of 1 year
Secondary Recurrence-free survival (RFS) RFS is defined as the duration from the date of the first documented response of CRc to the date of the first documented recurrence or death. through study completion, an average of 1 year
See also
  Status Clinical Trial Phase
Terminated NCT03541369 - Safety, Tolerability, PK, PD, and Efficacy of AMG 427 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia Phase 1
Recruiting NCT05143996 - CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) Phase 1
Completed NCT02626338 - Pilot Study of Crenolanib Combined With Standard Salvage Chemotherapy in Subjects With R/R AML Phase 1/Phase 2
Not yet recruiting NCT05662904 - Genetic Ablation of CD33 in HSC to Broaden the Therapeutic Index of CD33-directed Immunotherapy in Patients With AML Phase 1